Nagender Mankan, MD

Northwest Georgia Oncology Centers, P.C. North Fulton Cancer Center 2500 Hospital Blvd.
Suite 490
Roswell, GA 30076
Phone: (470) 321-7500
Fax: (678) 355-4474

Nagender Mankan, MD received his medical degree from Osmania Medical College in Hyderabad, India and has treated all forms of cancer and blood disorders. He is board certified in internal medicine, medical oncology and hematology.

Dr. Mankan currently¬†provides patient-centered cancer care at NGOC’s North Fulton Cancer Center.

Personal DataBirthplace: India
Medical EducationOsmania Medical College, Hyderabad, India M.B.B.S., 1996
Postdoctoral TrainingMRCP (U.K) 2000.
Residency (Internal Medicine)
Coney Island Hospital
Brooklyn, New York, June 2000 to June 2003

Fellowship (Hematology-Oncology)
Maimonides Medical Center
Brooklyn, New York, completed June 2006
Board CertificationAmerican Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology
American Board of Internal Medicine, Hematology
Medical LicensureState of Georgia, Physician License # 57887
Major Research InterestsCo-investigator/participated in the following trials while at South Georgia Medical Center:

C80405 A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin
with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and
Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

E3598 A Phase III Trial of Carboplatin, Paclitaxel, and Thoracic Radiotherapy, with or
without Thalidomide, in Patients with Stage III NSCLC

E5202 Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin vs
5-FU, Leucovorin, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer at
High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular
Markers

PACCT-1 Program for the Assessment of Clinical Cancer Tests: Trial Assigning
Individualized Options for Treatment: The TAILORx Trial

Novartis CICL670AUS22: A Prospective Non-Interventional Multicenter Registry in Iron
Overloaded Lower-risk Myelodysplastic Patients [More Registry]